Followers | 43 |
Posts | 4265 |
Boards Moderated | 0 |
Alias Born | 07/14/2010 |
Monday, June 28, 2021 11:57:06 AM
Profitability
Profit Margin -288.47%
Operating Margin (ttm) -291.05%
Management Effectiveness
Return on Assets (ttm) -18.17%
Return on Equity (ttm) -37.46%
Income Statement
Revenue (ttm) 51.52M
Revenue Per Share (ttm) 0.86
Quarterly Revenue Growth (yoy) -50.10%
Gross Profit (ttm) -92.41M
EBITDA -143.6M
Net Income Avi to Common (ttm) -148.63M
Diluted EPS (ttm) -2.47
Balance Sheet
Total Cash (mrq) 584.06M
Total Cash Per Share (mrq) 8.57
Total Debt (mrq) 72.74M
Total Debt/Equity (mrq) 13.33
Current Ratio (mrq) 9.90
Book Value Per Share (mrq) 8.04
Cash Flow Statement
Operating Cash Flow (ttm) -63.74M
Levered Free Cash Flow (ttm) -45.03M
Recent NTLA News
- Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting • GlobeNewswire Inc. • 09/12/2024 11:30:00 AM
- Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 09/03/2024 08:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:06:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:45:09 AM
- Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 08/08/2024 11:30:00 AM
- Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 08:17:08 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 08:13:01 PM
- Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 07/24/2024 08:01:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/18/2024 08:03:06 PM
- Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law Firm • PR Newswire (US) • 07/02/2024 04:53:00 PM
- Intellia Therapeutics Announces CFO Transition • GlobeNewswire Inc. • 06/26/2024 11:30:00 AM
- Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform • GlobeNewswire Inc. • 06/25/2024 07:30:00 PM
- Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024 • GlobeNewswire Inc. • 06/17/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:24:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:21:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:20:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:18:01 PM
- Intellia Therapeutics Names Brian Goff to its Board of Directors • GlobeNewswire Inc. • 06/14/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:59:57 PM
- Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) • GlobeNewswire Inc. • 06/02/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:25:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:40:12 AM
- Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM